- SS Innovations, developer of innovative surgical robotic technologies, reported record second-quarter revenue of $13.9 million, up 39.4% year over year.
- First-half revenue reached $25.0 million, a 65.6% increase from the same period in 2025.
- The company’s SSi Mantra installations rose 30.4% to 30 systems during the quarter.
- The installed base reached 224 SSi Mantra systems across 12 countries, with 12,272 cumulative surgeries performed.
- U.S. and European regulatory milestones could become important catalysts, with the company targeting FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026.
- The company’s telesurgery achievements are extending the clinical profile of SSi Mantra, while system installations remain the primary commercial growth driver.
SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, delivered another quarter of rapid top-line growth as demand for its SSi Mantra surgical robotic system continued to expand. The company reported second-quarter 2026 revenue of $13.9 million, an increase of 39.4% from $10.0 million a year earlier. Gross profit increased 20.0% to $7.1 million, although gross margin declined to 50.9% from 59.1% in the year-earlier quarter (https://ibn.fm/8BHJn).
The stronger comparison comes over the first six months of the year. Revenue reached $25.0 million, up 65.6% from $15.1 million in the first half of 2025. Gross profit increased 77.5% to $12.4 million, while first-half gross margin improved to 49.6% from 46.3%.
Additionally, SS Innovations installed 30 SSi Mantra systems during the second quarter, compared with 23 in the same period last year. For the first half, installations reached 56, versus 38 in the first half of 2025, representing growth of 47.4%. That brought the cumulative installed base to 224 systems across 12 countries as of June 30. The systems had been used in 12,272 surgeries, including 175 telesurgeries, 637 cardiac procedures, and 222 pediatric procedures.
The SSi Mantra is a modular system with three to five robotic arms, an ergonomic surgeon console, a 3D 4K display and instruments designed for procedures ranging from urology and gynecology to cardiac and pediatric surgery. That breadth matters because robotic surgery is not a single-procedure market. A system capable of supporting multiple specialties can potentially increase utilization at hospitals while creating additional demand for instruments and related services.
SS Innovations has also been using clinical training and telesurgery to expand the system’s capabilities and visibility. In April, the company hosted the Global Multi-Specialty Robotic Surgery Conference in New Delhi, which it said attracted more than 1,600 in-person attendees and 1,800 virtual participants from 19 countries.
In May, surgeons completed a telesurgery between Australia and India using SSi Mantra. In June, the company announced a robotic-assisted cardiac procedure conducted between Guyana and India across approximately 12,500 miles of fiber-network distance.
Then, after the quarter ended, SS Innovations reported another milestone. On July 29, surgeons led by Chief Executive Officer Dr. Sudhir Srivastava performed a robotic sleeve gastrectomy between Colombia and India across more than 13,600 miles of network distance. These procedures are notable from a technology-development standpoint, particularly because cardiac telesurgery remains an emerging application.
SS Innovations has emphasized affordability and accessibility as part of its strategy, but the SSi Mantra is not simply being positioned as a lower-cost substitute for established robotic systems. Its modular architecture, multi-specialty applications, cardiac capabilities and telesurgery functionality represent areas in which SSII is seeking to establish its own technological identity.
The company has received outside recognition as well. In June, SS Innovations won the Outstanding Company category at the 2026 Surgical Robotics Industry Awards, competing against nine other finalists. The company also graduated the first class from its specialized robotic cardiac surgery training program during the quarter.
Regulatory expansion remains another potentially important part of the investment thesis. SS Innovations said it expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. It is also pursuing European Union CE marking, which management believes could be obtained by the end of 2026.
Successful regulatory expansion would give SSII access to two of the world’s most important medical-device markets and provide a potential pathway for increasing the geographic diversity of future system sales.
Financially, the company entered the second half of 2026 with $13.6 million in cash and cash equivalents, excluding restricted cash, and no long-term debt. That balance sheet position provides an important backdrop as SS Innovations continues investing in commercialization, regulatory activities, manufacturing and international expansion.
With 56 systems installed during the first half, 224 systems already operating across 12 countries and revenue growth well ahead of the prior year, the company has established measurable commercial momentum. The potential U.S. and European regulatory milestones could determine how far that momentum can extend beyond its established Indian market.
“We remain enthusiastic about our ability to lead our foundational market of India, which is immense and growing, while expanding our global footprint in underserved countries and aiming for entry into the United States and European Union,” said Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations. “Our SSI Mantra has been engineered for precision, built to perform, and created to democratize access to advanced surgical robotic care—all underpinning our confidence in the future.”
For more information, visit the company’s website at www.SSInnovations.com.
NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
About QualityStocks
QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer
QualityStocks
Austin, Texas
www.QualityStocks.com
512.354.7000 Office
Editor@QualityStocks.com
QualityStocks is powered by IBN
